Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)

Inclusion Criteria: * Age ≥ 18 years old, male or female * For patients who have been diagnosed with ITP, the diagnostic criteria are consistent with the Chinese Expert Consensus on Diagnosis and Treatment of Primary Immune Thrombocytopenia (2016 Edition) * Recurrence after previous treatment with glucocorticoids is ineffective or effective * No contraindications to rhTPO (Terbyus) application, and willing to accept rhTPO treatment * Platelet count before enrollment ≤ 30 × 109 / L, or \> 30 × 109 / L but with active bleeding * Volunteer to participate in the study and sign the informed consent form Exclusion Criteria: * pregnant or lactating * Those with a history of thrombosis * severe cardiopulmonary liver and kidney dysfunction: creatinine level ≥ 176.8μmol / l (2mg / dl), transaminase, bilirubin levels higher than the upper limit of the normal value of 3 times * Those who have used rhTPO in the past 2 weeks, or who have undergone splenectomy within 2 months, or who have been treated with danazol for less than 1 month, or have recently applied the following ITP treatments but have not yet reached the efficacy judgment time. : C-ball (7 days), vincristine or vinblastine amide or rhIL-11 (2 weeks), Eltrombopag (1 month), or rituximab (2 months) * In the case of previous treatment of rhTPO: rhTPO 300U/kg/d, 14 days of treatment is invalid; * Severe or uncontrollable infections * have a history of mental illness * The investigator believes that the patient is not eligible to participate in any other circumstances of the trial.